Dream Pharma signs exclusive license agreement with Addrenex

Published: 2009-08-12 06:56:00

Updated: 2009-08-12 06:56:00

Dream Pharma, a division of Hanwha Group, said on August 4 that it signed an exclusive licensing agreement with the US-based Addrenex Pharmaceuticals to market a sustained-release formulation of Clonicel (clonidine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in Korea.

ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of i...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.